Valuation : Genmab A/S

Market Cap 13TCr 2TCr 1.72TCr 1.61TCr 1.47TCr 2.78TCr 1,91000Cr 2.79TCr 19TCr 7.47TCr 96TCr 7.5TCr 7.34TCr 3,19700Cr P/E 2026 *
27.3x
P/E 2027 * 19.2x
Enterprise Value 15TCr 2.3TCr 1.98TCr 1.86TCr 1.69TCr 3.19TCr 2,19500Cr 3.2TCr 22TCr 8.59TCr 1,10800Cr 8.62TCr 8.43TCr 3,67300Cr EV / Sales 2026 *
5.11x
EV / Sales 2027 * 4.14x
Free-Float
95.42%
Yield 2026 *
-
Yield 2027 * -
1 day-0.51%
1 week+0.23%
Current month+16.01%
1 month+13.00%
3 months+26.86%
6 months+16.64%
Current year+6.36%
1 week 2,092
Extreme 2092
2,198
1 month 1,819.5
Extreme 1819.5
2,198
Current year 1,512
Extreme 1512
2,257
1 year 1,512
Extreme 1512
2,257
3 years 1,157
Extreme 1157
2,710
5 years 1,157
Extreme 1157
3,327
10 years 786.2
Extreme 786.2
3,327
Manager TitleAgeSince
Chief Executive Officer 65 01/06/2010
Director of Finance/CFO 48 01/03/2020
Chief Tech/Sci/R&D Officer - 16/08/2024
Director TitleAgeSince
Director/Board Member 75 01/11/2003
Director/Board Member 58 01/01/2015
Director/Board Member 75 01/01/2015
Date Insider Type Main position Quantity % Market Cap.
01/12/25 Fiscal year

Director

189 0.0003%
01/12/25 Fiscal year

Director

283 0.0004%
01/12/25 Fiscal year

Director

189 0.0003%
Change 5-day change 1-year change 3-year change Capi.($)
-0.51%+0.23%+33.71%-18.02% 2TCr
-1.59%-3.35%+64.49%+98.69% 6.95TCr
-1.34%-0.75%+48.56%+90.63% 6.5TCr
-8.37%-12.43%+0.14%-15.42% 2.56TCr
-2.35%-5.75%-12.17%+448.29% 2.59TCr
+0.30%-0.69%+63.18%+11.93% 2.65TCr
-0.96%+10.36%+278.86%+438.78% 2.02TCr
-1.91%-4.37%+13.33%+531.29% 1.57TCr
-1.47%+0.68%+43.67%+145.49% 1.35TCr
-1.83%+3.29%+22.09%+195.17% 1.23TCr
Average -2.00%-1.40%+55.58%+192.68% 2.94TCr
Weighted average by Cap. -1.93%-1.30%+55.68%+154.60%

Financials

2026 *2027 *
Net sales 2.9TCr 449.75Cr 387.55Cr 363.36Cr 331.7Cr 624.87Cr 43TCr 626.86Cr 4.31TCr 1.68TCr 22TCr 1.69TCr 1.65TCr 72TCr 3.37TCr 523.82Cr 451.37Cr 423.21Cr 386.33Cr 727.78Cr 50TCr 730.1Cr 5.02TCr 1.96TCr 25TCr 1.97TCr 1.92TCr 84TCr
Net income 492.76Cr 77Cr 66Cr 62Cr 56Cr 106.29Cr 7.31TCr 106.63Cr 733.3Cr 286.11Cr 3.69TCr 287.23Cr 280.98Cr 12TCr 717.09Cr 111.33Cr 96Cr 90Cr 82Cr 154.68Cr 11TCr 155.17Cr 1.07TCr 416.36Cr 5.37TCr 417.99Cr 408.89Cr 18TCr
Net Debt 1.92TCr 297.98Cr 256.77Cr 240.75Cr 219.77Cr 414.01Cr 28TCr 415.33Cr 2.86TCr 1.11TCr 14TCr 1.12TCr 1.09TCr 48TCr 1.1TCr 171.17Cr 147.49Cr 138.29Cr 126.24Cr 237.81Cr 16TCr 238.57Cr 1.64TCr 640.14Cr 8.26TCr 642.64Cr 628.66Cr 27TCr
Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.4%); - income from sales of products (10.7%); - other (5.9%): primarily income from partnership agreement. Net sales are distributed geographically as follows: Denmark (89.4%), the United States (4.9%) and Japan (5.7%).
Employees
3,119
Date Price Change Volume
28/26/28 DKK 2,156.00 -0.51% 80,778
27/26/27 DKK 2,167.00 +0.37% 71,248
26/26/26 DKK 2,159.00 -1.68% 1,00,182
25/26/25 DKK 2,196.00 +3.98% 1,03,642
24/26/24 DKK 2,112.00 -1.81% 1,03,114
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
18
Last Close Price
2,156.00DKK
Average target price
2,427.12DKK
Spread / Average Target
+12.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GMAB Stock